Purchase this article with an account.
E. Y. Chew, T. E. Clemons, M. L. Klein, E. Agron, F. L. Ferris, III, Age-Related Eye Disease Study Group; Effect Modifiers of Progression to Advanced AMD Using the Age-Related Eye Disease Study (AREDS) Simple Scale. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1625.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To provide 5- and 10-year advanced AMD (AAMD) modified progression rates in AREDS participants using the AREDS simplified clinical scale for participants with drusen ≥ 250 µ and smoking history.
The AREDS simple scale specifies risk categories for a person to develop advanced AMD, defined as neovascular AMD or geographic atrophy that involves the center of the macula. The 5-step scale is based on the presence or absence in each eye of 2 easily identified retinal abnormalities or factors, large drusen (≥ 125µ) and pigment abnormalities. We look at modifications to the 5 and 10 year risks of developing advanced AMD (AAMD) when taking into consideration the presence of giant drusen (≥ 250µ) and/or smoking history.
The modified risks are based on 3,619 participants at risk for progression to AAMD both eyes (AMD Category 1, 2 an 3) and 788 participants with AAMD in the fellow eye (AMD Category 4). The estimated 5-year probabilities and 10-year probabilities of AAMD (5-year // 10-year) are shown in the table for participants with giant drusen and by smoking history.
In a predictable way, including the presence of giant drusen ≥ 250µ and/or smoking modifies the in simple scale scores’ risk to progression to AAMD. This can be helpful in discussing risk of progression with patients or identifying risk groups for eligibility in a clinical trial.
This PDF is available to Subscribers Only